BLAINJECTIONINJECTABLE
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
ZIRABEV (bevacizumab-bvzr) by Pfizer is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2019.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIRABEV (bevacizumab-bvzr) is a biosimilar monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis. It is a VEGF-directed antibody used across multiple oncology and ophthalmology indications where blocking blood vessel formation to tumors or pathologic neovascularization is therapeutically relevant. The drug works by binding VEGF and preventing its interaction with endothelial growth factor receptors.
$0.009BPart D
PeakStable
ZIRABEV is in peak lifecycle with modest Part D spending ($9M) but faces significant competitive pressure (30/100); career opportunities are maintenance-focused rather than high-growth.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Started May 2025
0Non-small Cell Lung CancerMetastatic Colorectal CancerMetastatic Breast Cancer+5 more
Why This Matters for Your Career
Worked on ZIRABEV at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.